Nutrabiotech Istradefylline 98% 1G Powder, high purity Istradefylline KW-6002 powder, selective A2A adenosine receptor antagonist, basal ganglia regulator, Parkinson’s disease neurological research raw material

Istradefylline CAS 155270-99-8 98% Purity Adenosine A2A Receptor Antagonist

High purity Istradefylline powder CAS 155270-99-8 with 98% HPLC purity. Selective Adenosine A2A receptor antagonist for Parkinson’s disease research, factory bulk supply, complete certificates, fast global shipping for lab pharmaceutical research.
Category: Tags: , , , , , ,
Istradefylline KW-6002 (CAS 155270-99-8) Adenosine A2A Antagonist | Parkinson's Research

Istradefylline CAS 155270-99-8
Selective Adenosine A2A Receptor Antagonist (Parkinson's)

Istradefylline (CAS 155270-99-8), also KW-6002, is a selective adenosine A2A receptor antagonist used as an adjunct in Parkinson's disease. By blocking A2A receptors that oppose dopaminergic D2 signaling in the striatopallidal pathway, it enhances motor function and augments levodopa without worsening dyskinesia. Formula C20H24N4O4, MW 384.4. Research-grade with COA.

A2A AntagonistAdenosineParkinson'sIstradefyllineKW-6002DopamineMovementNeurology
Request a Quote Technical Specs
384.4
MW (C20H24N4O4)
≥98%
Purity (HPLC)
A2A
Adenosine block

Molecular Information

Name: Istradefylline (KW-6002)
CAS: 155270-99-8
Formula: C20H24N4O4
MW: 384.4 g/mol
Class: Adenosine A2A receptor antagonist
Core: Xanthine (purinedione) derivative
Target: Adenosine A2A receptor
Activity: Striatopallidal D2 modulation
MP: Not firmly reported
Appearance: White to off-white powder
Synonyms: KW-6002
Storage: -20°C, protect from light
155270-99-8
🧪
CAS Number
384.4
⚖️
Molecular Weight
A2A Antagonist
🎯
Primary Activity
≥98%
✅
Purity

Product Technical Specifications

Complete physicochemical properties and QC parameters for Istradefylline (CAS 155270-99-8)

📋 Physicochemical Properties

  • Product NameIstradefylline (KW-6002)
  • IUPAC Name8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
  • CAS Number155270-99-8
  • SynonymsIstradefylline; KW-6002
  • Molecular FormulaC20H24N4O4
  • Molecular Weight384.4 g/mol
  • SourceSynthetic xanthine derivative
  • AppearanceWhite to off-white powder
  • Water SolubilityLow
  • Organic SolubilityDMSO; ethanol
  • Compound ClassAdenosine A2A antagonist / anti-Parkinsonian
  • HS Code2934.99

🔬 Quality Control & Handling

  • Purity (HPLC)≥98%
  • FormCrystalline powder
  • Primary TargetAdenosine A2A receptor
  • Assay ReadoutMotor / dyskinesia readouts
  • SelectivityA2A vs other adenosine subtypes
  • Storage Condition-20°C, sealed, protect from light
  • Solution StabilityDMSO stock stable weeks at -20°C
  • ShippingRoom temp / cold chain
  • QC DocumentationCOA / HPLC / NMR / MS / MSDS
  • Pack Sizes100mg / 500mg / 1g / 5g / 10g
  • Stock StatusIn Stock
  • Use StatementResearch use only; not for human/clinical use

Key Molecular Targets & Pathway Nodes

Istradefylline engages the molecular machinery and pathway nodes that define its research utility.

🧬 Adenosine A2A receptor 🧬 Striatopallidal pathway 🧬 Dopamine D2 (indirect) 🧭 Motor circuits 🧪 cAMP / PKA 🧭 Movement disorders 🔬 Receptor profiling 🦴 Neuroprotection 💧 Glutamate mod 🧬 Adenosine system

How Istradefylline Works: Unmasking Dopaminergic Tone

Istradefylline blocks A2A receptors in the indirect pathway, amplifying dopamine signaling in Parkinson's

1

Antagonism of Adenosine A2A Receptors

Istradefylline selectively blocks A2A adenosine receptors concentrated in the striatopallidal (indirect) pathway of the basal ganglia.

2

Reversal of D2 Opposition

A2A activation normally opposes dopaminergic D2 signaling. Blocking A2A relieves this inhibition, effectively enhancing dopaminergic transmission without adding dopamine.

3

Motor Improvement Without Dyskinesia

The net effect is improved motor function and augmented levodopa response, used as an adjunct in Parkinson's disease with little increase in dyskinesia.

⚖️ Istradefylline vs Comparators

  • Istradefylline (this product)Selective A2A antagonist; levodopa adjunct
  • CaffeineNon-selective adenosine antagonist
  • Preladenant / vipadenantOther A2A antagonists
  • Selective EdgeA2A-focused; CNS motor pathway
  • Research NicheParkinson's & movement disorders

♻️ Downstream Biological Consequences

  • ReceptorA2A blocked
  • PathwayIndirect striatopallidal relieved
  • DopamineD2 signaling enhanced
  • MotorFunction improved
  • LevodopaResponse augmented
  • DyskinesiaMinimal increase

Research Applications & Models

Istradefylline is the reference A2A antagonist for Parkinson's and movement-disorder research.

🧭

Parkinson's Disease Research

The benchmark A2A antagonist studied as a levodopa adjunct for motor symptoms.

Parkinson's
🧬

Adenosine Receptor Studies

Probes A2A selectivity and adenosine-system pharmacology.

A2A
🧭

Movement-Disorder Models

Evaluates motor function, akinesia and dyskinesia.

Movement
🧪

Neuropharmacology

Investigates basal-ganglia and striatal signaling.

Neuro
🔬

Drug-Discovery Screening

Adenosine-antagonist and CNS lead optimization.

Screening
🦴

Neuroprotection

Studied for glial and neuroprotective phenotypes.

Neuroprotect

Key Literature & Landmark Publications

Landmark work on adenosine A2A antagonists in Parkinson's disease.

Kanda T, et al. KW-6002 (istradefylline) adenosine A2A antagonist in Parkinson's models.
Landmark reference
Investigator reports. Istradefylline as levodopa adjunct (clinical).
Landmark reference
Review. Adenosine A2A receptors in basal ganglia dysfunction.
Landmark reference
Structure-activity literature. Xanthine A2A antagonists.
Landmark reference
Preclinical reports. Istradefylline motor and dyskinesia readouts.
Landmark reference

Available Sizes & Ordering

Research-grade Istradefylline / KW-6002 (CAS 155270-99-8) with full QC documentation; standard packs and bulk custom quantities supported.

TierPack SizeStock StatusSuitable ForLead Time
Standard100mgIn StockReceptor / neuro assaysSame/next-day ship
Medium500mgIn StockCell & binding studiesSame/next-day ship
Large1gIn StockIn vivo PD modelsSame/next-day ship
Bulk5gIn StockScreening & formulationQuote to confirm
Industrial10g+Made to orderProcess developmentBatch delivery

💡 Reference sizes shown above; for exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is istradefylline and what does it block?
Istradefylline (CAS 155270-99-8), also KW-6002, is a selective adenosine A2A receptor antagonist used as an adjunct in Parkinson's disease. Formula C20H24N4O4, MW 384.4.
How does it help Parkinson's disease?
A2A receptors oppose dopaminergic D2 signaling in the striatopallidal pathway. Blocking them enhances dopamine transmission, improving motor function and augmenting levodopa without marked dyskinesia.
Is istradefylline a dopamine drug?
No — it does not add dopamine; it modulates adenosine signaling to unmask existing dopaminergic tone, which is why it is used adjunctively.
What readouts confirm activity?
A2A receptor binding/functional assays, motor-behavior tests, and striatal cAMP / locomotor readouts.
How soluble is istradefylline and how should it be prepared?
It is soluble in DMSO and ethanol; poorly in water. Prepare a DMSO stock, dilute into medium (final DMSO ≤0.1% v/v), and store at -20°C protected from light.
Is QC documentation provided?
Every batch ships with a Certificate of Analysis (COA) including HPLC purity, NMR structural confirmation and MS data; MSDS/SDS and Certificates of Origin are available on request.

Need Istradefylline for Your Research?

Research-grade Istradefylline (CAS 155270-99-8) — purity ≥98% HPLC, COA included
Selective A2A Antagonist — request a quote today

Request a Quote →
Weight 1 g

Related products